Literature DB >> 21975843

[Volume replacement therapy options for critically ill patients].

C J Wiedermann1.   

Abstract

For critically ill patients with hypovolemia, volume replacement therapy is important to maintain sufficient tissue perfusion and oxygenation. Nearly all patients receive crystalloids and often additionally colloids. The advantages of the former are low costs, immediate availability, the ability to fill both the intravascular and extravascular fluid spaces and a non-allergenic potential. Administration of excessive fluid with extravasation can, however, be a problem with crystalloids and promotes the formation of tissue edema, particularly with large volumes. Colloids are more efficient volume expanders and tissue edema can be avoided. The disadvantages compared to crystalloids are the higher costs and the risk of rare but potentially severe anaphylactic reactions. Artificial colloids (hydroxyethyl starch) are cheaper than the natural colloid albumin but the safety profile is less favorable.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975843     DOI: 10.1007/s00063-011-0023-8

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  15 in total

1.  Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis.

Authors:  Simon Finfer; Suzanne McEvoy; Rinaldo Bellomo; Colin McArthur; John Myburgh; Robyn Norton
Journal:  Intensive Care Med       Date:  2010-10-06       Impact factor: 17.440

2.  The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock.

Authors:  Bertrand Guidet; Guillermo Jasso Mosqueda; Gaël Priol; Philippe Aegerter
Journal:  J Crit Care       Date:  2007-02-08       Impact factor: 3.425

Review 3.  Update on the comparative safety of colloids: a systematic review of clinical studies.

Authors:  A B Johan Groeneveld; Roberta J Navickis; Mahlon M Wilkes
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

4.  Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery.

Authors:  Artyom Sedrakyan; Kathleen Gondek; David Paltiel; John A Elefteriades
Journal:  Chest       Date:  2003-06       Impact factor: 9.410

5.  Saline or albumin for fluid resuscitation in patients with traumatic brain injury.

Authors:  John Myburgh; D James Cooper; Simon Finfer; Rinaldo Bellomo; Robyn Norton; Nicole Bishop; Sing Kai Lo; Shirley Vallance
Journal:  N Engl J Med       Date:  2007-08-30       Impact factor: 91.245

6.  Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials.

Authors:  Jean-Louis Vincent; Roberta J Navickis; Mahlon M Wilkes
Journal:  Crit Care Med       Date:  2004-10       Impact factor: 7.598

7.  The risk associated with hyperoncotic colloids in patients with shock.

Authors:  Frédérique Schortgen; Emmanuelle Girou; Nicolas Deye; Laurent Brochard
Journal:  Intensive Care Med       Date:  2008-08-07       Impact factor: 17.440

8.  Intensive insulin therapy and pentastarch resuscitation in severe sepsis.

Authors:  Frank M Brunkhorst; Christoph Engel; Frank Bloos; Andreas Meier-Hellmann; Max Ragaller; Norbert Weiler; Onnen Moerer; Matthias Gruendling; Michael Oppert; Stefan Grond; Derk Olthoff; Ulrich Jaschinski; Stefan John; Rolf Rossaint; Tobias Welte; Martin Schaefer; Peter Kern; Evelyn Kuhnt; Michael Kiehntopf; Christiane Hartog; Charles Natanson; Markus Loeffler; Konrad Reinhart
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

Review 9.  Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies.

Authors:  Christian J Wiedermann; Wolfgang Wiedermann; Michael Joannidis
Journal:  Intensive Care Med       Date:  2010-06-02       Impact factor: 17.440

10.  Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials.

Authors:  Christian J Wiedermann; Stefan Dunzendorfer; Luigi U Gaioni; Francesco Zaraca; Michael Joannidis
Journal:  Crit Care       Date:  2010-10-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.